Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy
Charcot–Marie–Tooth disease 1A (CMT1A) is a peripheral demyelinating disease. Here, the authors demonstrate in a rodent model of CMT1A that Schwann cells have impairments in lipid biosynthesis, and that restoring lipids via diet can reverse the dysmyelinating phenotype in these animals.
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2018-08-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-018-05420-0 |
| id |
doaj-8b8e4e83c023447f9c6cbe01a5ec8a8b |
|---|---|
| record_format |
Article |
| spelling |
doaj-8b8e4e83c023447f9c6cbe01a5ec8a8b2021-05-11T09:48:20ZengNature Publishing GroupNature Communications2041-17232018-08-019111410.1038/s41467-018-05420-0Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathyR. Fledrich0T. Abdelaal1L. Rasch2V. Bansal3V. Schütza4B. Brügger5C. Lüchtenborg6T. Prukop7J. Stenzel8R. U. Rahman9D. Hermes10D. Ewers11W. Möbius12T. Ruhwedel13I. Katona14J. Weis15D. Klein16R. Martini17W. Brück18W. C. Müller19S. Bonn20I. Bechmann21K. A. Nave22R. M. Stassart23M. W. Sereda24Department of Neurogenetics, Max-Planck-Institute of Experimental MedicineDepartment of Neurogenetics, Max-Planck-Institute of Experimental MedicineDepartment of Neurogenetics, Max-Planck-Institute of Experimental MedicineCenter for Molecular Neurobiology, Institute of Medical Systems Biology, University Medical Center Hamburg-EppendorfDepartment of Neurogenetics, Max-Planck-Institute of Experimental MedicineHeidelberg University Biochemistry Center (BZH)Heidelberg University Biochemistry Center (BZH)Department of Neurogenetics, Max-Planck-Institute of Experimental MedicineDepartment of Neurogenetics, Max-Planck-Institute of Experimental MedicineCenter for Molecular Neurobiology, Institute of Medical Systems Biology, University Medical Center Hamburg-EppendorfDepartment of Neurogenetics, Max-Planck-Institute of Experimental MedicineDepartment of Neurogenetics, Max-Planck-Institute of Experimental MedicineDepartment of Neurogenetics, Max-Planck-Institute of Experimental MedicineDepartment of Neurogenetics, Max-Planck-Institute of Experimental MedicineInstitute of Neuropathology, University Hospital AachenInstitute of Neuropathology, University Hospital AachenDepartment of Neurology, Section of Developmental Neurobiology, University Hospital WuerzburgDepartment of Neurology, Section of Developmental Neurobiology, University Hospital WuerzburgInstitute of Neuropathology, University Medical Center GöttingenDepartment of Neuropathology, University Hospital LeipzigCenter for Molecular Neurobiology, Institute of Medical Systems Biology, University Medical Center Hamburg-EppendorfInstitute of Anatomy, University of LeipzigDepartment of Neurogenetics, Max-Planck-Institute of Experimental MedicineDepartment of Neurogenetics, Max-Planck-Institute of Experimental MedicineDepartment of Neurogenetics, Max-Planck-Institute of Experimental MedicineCharcot–Marie–Tooth disease 1A (CMT1A) is a peripheral demyelinating disease. Here, the authors demonstrate in a rodent model of CMT1A that Schwann cells have impairments in lipid biosynthesis, and that restoring lipids via diet can reverse the dysmyelinating phenotype in these animals.https://doi.org/10.1038/s41467-018-05420-0 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
R. Fledrich T. Abdelaal L. Rasch V. Bansal V. Schütza B. Brügger C. Lüchtenborg T. Prukop J. Stenzel R. U. Rahman D. Hermes D. Ewers W. Möbius T. Ruhwedel I. Katona J. Weis D. Klein R. Martini W. Brück W. C. Müller S. Bonn I. Bechmann K. A. Nave R. M. Stassart M. W. Sereda |
| spellingShingle |
R. Fledrich T. Abdelaal L. Rasch V. Bansal V. Schütza B. Brügger C. Lüchtenborg T. Prukop J. Stenzel R. U. Rahman D. Hermes D. Ewers W. Möbius T. Ruhwedel I. Katona J. Weis D. Klein R. Martini W. Brück W. C. Müller S. Bonn I. Bechmann K. A. Nave R. M. Stassart M. W. Sereda Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy Nature Communications |
| author_facet |
R. Fledrich T. Abdelaal L. Rasch V. Bansal V. Schütza B. Brügger C. Lüchtenborg T. Prukop J. Stenzel R. U. Rahman D. Hermes D. Ewers W. Möbius T. Ruhwedel I. Katona J. Weis D. Klein R. Martini W. Brück W. C. Müller S. Bonn I. Bechmann K. A. Nave R. M. Stassart M. W. Sereda |
| author_sort |
R. Fledrich |
| title |
Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy |
| title_short |
Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy |
| title_full |
Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy |
| title_fullStr |
Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy |
| title_full_unstemmed |
Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy |
| title_sort |
targeting myelin lipid metabolism as a potential therapeutic strategy in a model of cmt1a neuropathy |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2018-08-01 |
| description |
Charcot–Marie–Tooth disease 1A (CMT1A) is a peripheral demyelinating disease. Here, the authors demonstrate in a rodent model of CMT1A that Schwann cells have impairments in lipid biosynthesis, and that restoring lipids via diet can reverse the dysmyelinating phenotype in these animals. |
| url |
https://doi.org/10.1038/s41467-018-05420-0 |
| work_keys_str_mv |
AT rfledrich targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT tabdelaal targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT lrasch targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT vbansal targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT vschutza targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT bbrugger targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT cluchtenborg targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT tprukop targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT jstenzel targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT rurahman targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT dhermes targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT dewers targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT wmobius targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT truhwedel targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT ikatona targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT jweis targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT dklein targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT rmartini targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT wbruck targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT wcmuller targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT sbonn targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT ibechmann targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT kanave targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT rmstassart targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy AT mwsereda targetingmyelinlipidmetabolismasapotentialtherapeuticstrategyinamodelofcmt1aneuropathy |
| _version_ |
1721449180683042816 |